Back to top
more

XOMA Royalty Corporation (XOMA)

(Delayed Data from NSDQ)

$26.50 USD

26.50
38,873

+0.66 (2.55%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $26.34 -0.16 (-0.60%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +22.43% and +4.82%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Novavax (NVAX) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Novavax (NVAX) delivered earnings and revenue surprises of +985.71% and +102.74%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

XOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last?

by Zacks Equity Research

XOMA Royalty (XOMA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

XOMA Royalty (XOMA) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

XOMA Royalty (XOMA) delivered earnings and revenue surprises of 123.08% and 159.58%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Stoke Therapeutics (STOK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

What Makes XOMA Royalty (XOMA) a New Buy Stock

by Zacks Equity Research

XOMA Royalty (XOMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

XOMA Royalty (XOMA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

XOMA Royalty (XOMA) delivered earnings and revenue surprises of 11.36% and 8.06%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

XOMA Royalty (XOMA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

XOMA Royalty (XOMA) delivered earnings and revenue surprises of -7.69% and 32.45%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

TELA Bio (TELA) delivered earnings and revenue surprises of -13.33% and 15.31%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

iTeos Therapeutics (ITOS) delivered earnings and revenue surprises of 82.69% and 733.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

MaxCyte (MXCT) delivered earnings and revenue surprises of 35.71% and 27.18%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Xoma (XOMA) Surges 6.4%: Is This an Indication of Further Gains?

by Zacks Equity Research

Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Xoma (XOMA) Soars 15.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

Certara, Inc. (CERT) Q1 Earnings Meet Estimates

by Zacks Equity Research

Certara (CERT) delivered earnings and revenue surprises of 0% and 2.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of -11.11% and 3.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Xoma (XOMA) Moves 7.7% Higher: Will This Strength Last?

by Zacks Equity Research

Xoma (XOMA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 30.69% and 15.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Vertex (VRTX): Can Its 5.0% Jump Turn into More Strength?

by Zacks Equity Research

Vertex (VRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Xoma (XOMA) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Xoma (XOMA) delivered earnings and revenue surprises of -140% and 95.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Xoma (XOMA) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Xoma (XOMA) delivered earnings and revenue surprises of -381.82% and 88.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Xoma (XOMA) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Xoma (XOMA) delivered earnings and revenue surprises of 5.88% and 12.73%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -5.97% and 44.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Xoma (XOMA) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Xoma (XOMA) delivered earnings and revenue surprises of -466.67% and -85.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Xoma (XOMA) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.